IPSEN SA S/ADR (IPSEY)
IPSEY moved a median of 0.00% 30 minutes after news, and 0.00% by the close. How IPSEY actually reacts to news — the realized, point-in-time move the market made, measured across 294 labeled events over the last three years with zero look-ahead.
IPSEY’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 1% | 145 |
| 30-min | 0.00% | 6% | 147 |
| 60-min | 0.00% | 9% | 151 |
| to close | 0.00% | 14% | 193 |
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when IPSEY moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to IPSEY's baseline. Nothing else.
Recent IPSEY events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Ipsen completes acquisition of Kartos Therapeutics, strengthening late-stage Oncology pipeline | Press release | GlobeNewswire | — | — | |
| Ipsen delivers excellent H1 2026 results and upgrades its full-year guidance | Press release | GlobeNewswire | +0.00% | -2.20% | |
| Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset to Ipsen's Rare Disease pipeline | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Dysport® is the first botulinum toxin to achieve positive topline Phase III results in both episodic and chronic migraine. | Press release | GlobeNewswire | +0.02% | -0.47% | |
| Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio | Press release | GlobeNewswire | +0.00% | +0.00% | |
| New late-breaking data reinforces IQIRVO®’s impact on ALP, fatigue and pruritus in PBC | Press release | GlobeNewswire | — | — | |
| National Survey From Ipsen Shows Young People Are Not Prepared for the Shift From Pediatric to Adult Healthcare | Press release | Business Wire | — | — | |
| Ipsen unveils corabotase, a first-in-class recombinant neuroinhibitor, RNI™, at the SCALE Symposium | Press release | GlobeNewswire | — | — | |
| Ipsen delivers strong sales in the first quarter of 2026 and confirms its full-year guidance | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Ojemda® approved in the European Union as the first targeted therapy in relapsed or refractory pediatric low-grade glioma regardless of BRAF alteration | Press release | GlobeNewswire | — | — | |
| Ipsen appoints Michelle C. Werner as EVP, President of North America | Press release | GlobeNewswire | +0.00% | +2.02% | |
| Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma | Press release | GlobeNewswire | — | — | |
| Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-grade glioma | Press release | GlobeNewswire | — | — | |
| Ipsen delivers strong results in 2025, driven by solid execution across all therapeutic areas, and provides 2026 guidance | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Origami Therapeutics Announces Global Collaboration with Ipsen to Advance Protein Degrader Program | Press release | Business Wire | +0.00% | +0.00% | |
| Ipsen nominates Peter Guenter to its Board of Directors | Press release | GlobeNewswire | — | — | |
| Pierrick Lefranc appointed as Executive Vice President Technical Operations, member of Executive Leadership Team | Press release | GlobeNewswire | +0.00% | +0.00% | |
| New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS | Press release | GlobeNewswire | — | — | |
| U.S. FDA grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in first line unfit Acute Myeloid Leukemia | Press release | GlobeNewswire | — | — | |
| Ipsen expands early development pipeline with Simcere Zaiming’s innovative antibody drug conjugate | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Ipsen update on Phase II FALKON trial in patients with ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP) | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology pipeline | Press release | GlobeNewswire | — | — | |
| Ipsen mourns the passing of Henri Beaufour, a founding family Board member | Press release | GlobeNewswire | — | — | |
| Ipsen Launches Educational Initiative to Support Teens and Young Adults Moving From Pediatric to Adult Healthcare | Press release | Business Wire | +0.00% | -1.11% | |
| EQT Life Sciences' ImCheck Therapeutics to be acquired by Ipsen in a transaction valued at up to EUR 1 billion | Press release | PR Newswire | — | — | |
| Ipsen delivers strong sales in the first nine months of 2025 and further upgrades its full-year guidance | Press release | GlobeNewswire | — | — | |
| Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline | Press release | GlobeNewswire | — | — | |
| Ipsen’s LANTIC Phase II in aesthetics delivers a first-in-class, differentiated long-acting clinical profile for IPN10200, enabling the initiation of Phase III | Press release | GlobeNewswire | — | — | |
| Health Canada Approves Bylvay™ (odevixibat) for the treatment of cholestatic pruritus in patients with Alagille Syndrome | Press release | PR Newswire | — | — | |
| Ipsen delivers strong results in the first half of 2025 and upgrades its full-year guidance | Press release | GlobeNewswire | — | — | |
| Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors | Press release | GlobeNewswire | — | +0.00% | |
| Ipsen announces changes to its Executive Committee | Press release | GlobeNewswire | +0.00% | +3.74% | |
| Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors | Press release | GlobeNewswire | +0.00% | +0.43% | |
| Late-breaking exploratory data highlights the impact of IQIRVO® (elafibranor) on fatigue and provides mechanistic insights into anti-inflammatory and symptom-related effects in patients with primary biliary cholangitis | Press release | GlobeNewswire | — | — | |
| Ipsen appoints Laura Réveillon as EVP, Strategy & Transformation | Press release | GlobeNewswire | +0.00% | +3.56% | |
| Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance | Press release | GlobeNewswire | +0.00% | -0.44% | |
| Ipsen announces issuance of €500 million inaugural Rated Public Bond | Press release | GlobeNewswire | +0.00% | -0.15% | |
| Ipsen appoints Olivia Brown as Executive Vice-President, Global Head of Neurotoxins | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Marengo Therapeutics Announces Second Drug Candidate Nomination from Strategic Collaboration with Ipsen | Press release | PR Newswire | +0.00% | -1.32% | |
| Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025 | Press release | GlobeNewswire | +0.00% | -4.53% | |
| Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology | Press release | GlobeNewswire | +0.00% | -0.94% | |
| Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus | Press release | GlobeNewswire | — | — | |
| Ipsen receives its second Shingo Prize for operational excellence | Press release | GlobeNewswire | — | — | |
| Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors | Press release | GlobeNewswire | +0.00% | -4.21% | |
| Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis | Press release | GlobeNewswire | +0.00% | -4.21% | |
| Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential | Press release | GlobeNewswire | — | — | |
| Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial | Press release | GlobeNewswire | — | — | |
| Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis | Press release | GlobeNewswire | +0.00% | -1.37% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the IPSEY section they belong to.
Where else IPSEY is measured.
IPSEY earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| GeoVax Labs, Inc. (GOVX) | 296 | -0.65% | 35% |
| Processa Pharmaceuticals, Inc. (PCSA) | 296 | 0.00% | 50% |
| Adicet Bio, Inc. (ACET) | 293 | -0.83% | 36% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 293 | +0.08% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is IPSEN SA S/ADR's median reaction calculated?
Every labeled IPSEY news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 294 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 6% of IPSEY's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does IPSEY's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.